Tyeese L. Gaines DO
Dr. Tyeese L. Gaines, is a board-certified emergency medicine physician as well as a 15-year news veteran. Dr. Ty has a master's degree in journalism from Northeastern University and previously served as health editor of theGrio.com (Formerly MSNBC) for 3 years.
After interning at media outlets such as WAVE3 (NBC) in Louisville and WCVB (ABC) in Boston, she got her start as an associate producer for NBC6/WTVJ in Miami during medical school. Over the years, Dr. Ty has appeared as an on-air medical expert for local, online and national news shows and has written for various online, magazine and newspaper outlets. In 2011 was honored with a Top 40 under 40 award from the National Medical Association and she recently finished her Master of Business Administration degree from University of North Carolina - Chapel Hill.
Dr. Ty is a practicing emergency medicine physician. She completed her residency training at Yale-New Haven Hospital where she was chief resident, and later taught as a clinical instructor.
After interning at media outlets such as WAVE3 (NBC) in Louisville and WCVB (ABC) in Boston, she got her start as an associate producer for NBC6/WTVJ in Miami during medical school. Over the years, Dr. Ty has appeared as an on-air medical expert for local, online and national news shows and has written for various online, magazine and newspaper outlets. In 2011 was honored with a Top 40 under 40 award from the National Medical Association and she recently finished her Master of Business Administration degree from University of North Carolina - Chapel Hill.
Dr. Ty is a practicing emergency medicine physician. She completed her residency training at Yale-New Haven Hospital where she was chief resident, and later taught as a clinical instructor.
Recent Contributions to PracticeUpdate:
- ESMO 2018: Nivolumab Plus Ipilimumab in First-line Setting for MSI-H Metastatic Colon Cancer
- ESMO 2018: PT2977 for VHL-Associated Renal Cell Carcinoma
- ESMO 2018: Real World Effectiveness of Pazopanib in Patients With Intermediate Risk Renal Cell Carcinoma
- ESMO 2018: Darbepoeitin for Anemia in Patients With Advanced NSCLC
- ESMO 2018: Atezolizumab With Chemotherapy in First-line Treatment of Non-squamous NSCLC
- ESMO 2018: Atezolizumab Plus Fluoropyrimidine and Bevacizumab for Metastatic Colorectal Cancer
- ESMO 2018: Combination Strategies for Immunotherapy in Breast Cancer
- ESMO 2018: Atezolizumab Plus Nab-Paclitaxel for Advanced Triple Negative Breast Cancer
- ESMO 2018: Pembrolizumab With Radiation Therapy for Patients With Triple Negative Breast Cancer
- ESMO 2018: Dabrafenib and Trametinib Plus Pembrolizumab for BRAF-Mutant Melanoma